Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 36,601 shares of Cytokinetics stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the completion of the sale, the chief executive officer directly owned 430,330 shares of the company’s stock, valued at approximately $26,745,009.50. This trade represents a 7.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Cytokinetics Stock Performance

Shares of NASDAQ CYTK traded up $0.06 during midday trading on Wednesday, hitting $62.19. 1,983,803 shares of the stock traded hands, compared to its average volume of 1,895,650. The firm has a market capitalization of $7.66 billion, a P/E ratio of -9.52 and a beta of 0.56. Cytokinetics, Incorporated has a one year low of $29.31 and a one year high of $70.98. The firm has a 50-day moving average of $63.86 and a two-hundred day moving average of $60.93.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. Cytokinetics’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.26) earnings per share. Equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target on CYTK to $100 and kept an outperform rating, signaling strong upside versus the current price and supporting bullish investor expectations. Mizuho raises PT to $100
• Positive Sentiment: JPMorgan nudged its target up from $74 to $75 and maintains an overweight/positive stance, reinforcing the buy-side view. JPMorgan raises PT to $75
• Positive Sentiment: Barclays reiterated a Buy rating on CYTK, adding to a broad base of favorable analyst coverage and a consensus price-target materially above the current level. Barclays keeps Buy rating
• Neutral Sentiment: Cytokinetics granted options (8,628 shares) and 5,719 RSUs as inducements to five new hires — standard hiring compensation but modestly dilutive over time. Inducement grants announcement
• Neutral Sentiment: Coverage and valuation pieces (including assessments after MYQORZO trial data) keep attention on the drug pipeline; results and safety updates will remain key catalysts. MYQORZO valuation assessment
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold 36,601 shares (~$2.27M at ~\$62.15). Large insider disposals can signal liquidity needs or rebalancing and may pressure sentiment. CEO Form 4
• Negative Sentiment: Other senior executives sold notable blocks this week (EVP Fady I. Malik: 12,033 shares; EVP Andrew Callos: multiple sales including 1,930 and earlier lots; EVP Sung Lee: 4,935 shares), representing single-digit percentage ownership reductions—adds to selling narrative. EVP Form 4s

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright upped their price target on shares of Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Robert W. Baird set a $84.00 target price on shares of Cytokinetics in a research report on Tuesday, March 10th. The Goldman Sachs Group set a $95.00 target price on shares of Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Royal Bank Of Canada increased their price target on shares of Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Finally, Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average target price of $89.89.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new stake in Cytokinetics in the 4th quarter worth approximately $27,000. Kestra Advisory Services LLC purchased a new position in Cytokinetics during the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. purchased a new position in Cytokinetics during the fourth quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cytokinetics by 46.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares during the period. Finally, Quarry LP bought a new position in shares of Cytokinetics in the third quarter worth approximately $30,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.